Electromed, Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Electromed, Inc. develops, manufactures, markets, and sells medical devices that provide airway clearance therapy, primarily through its flagship product, the SmartVest Airway Clearance System. The SmartVest Systems utilize High Frequency Chest Wall Oscillation (HFCWO) technology to assist patients with compromised pulmonary function by facilitating mucus clearance. The company’s product portfolio includes the SmartVest SQL System, SmartVest Clearway System for inpatient hospital use, and single-patient-use SmartVest and SmartVest Wrap products. These devices are marketed to hospitals, home health care providers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and directly to patients, primarily in the United States, with distribution through both direct sales and home medical equipment distributors. Founded in 1992 and headquartered in New Prague, Minnesota, Electromed targets patients with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disorders. The company serves healthcare providers and patients by incorporating personalized therapy options, including recent expansions in SmartVest garment and generator color options to improve patient satisfaction and adherence. Recent major developments include Electromed’s strategic expansion of distribution channels via partnerships with national and regional home medical equipment distributors, enhancing access to the SmartVest in the U.S. home care market. In 2024, Electromed launched the SmartVest Clearway Airway Clearance System designed specifically for hospital inpatient use. The company also authorized a $10 million stock repurchase program in 2025, reflecting strong operational performance and robust cash reserves. Additionally, Electromed expanded access through a partnership in early 2024 aimed at veterans, federal employees, and Native American communities, advancing its mission to broaden patient reach. Electromed continues to focus on airway clearance innovation and market-driven solutions to support patients with chronic lung diseases, driving growth through product development, strategic partnerships, and expanded distribution while maintaining a strong market presence in the healthcare equipment and supplies sector.
Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Best Momentum Stocks to Buy for June 2nd
New Strong Buy Stocks for June 2nd
Electromed, Inc. (ELMD) Hits Fresh High: Is There Still Room to Run?
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes
Electromed, Inc. (ELMD)'s Technical Outlook is Bright After Key Golden Cross
Electromed (ELMD) is an Incredible Growth Stock: 3 Reasons Why
What Makes Electromed (ELMD) a Good Fit for 'Trend Investing'
5 High-Efficiency Stocks to Buy Now: HCSG, ELMD, UMBF, SHEL, MTSI
All You Need to Know About Electromed (ELMD) Rating Upgrade to Strong Buy
Electromed, Inc. (ELMD) Q3 Earnings and Revenues Top Estimates
Electromed, Inc. (ELMD) Q3 2026 Earnings Call Transcript
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
3 Reasons Growth Investors Will Love Electromed (ELMD)
Electromed: Some Short Term Gain But I Fear Long Term Pain
3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes
Here is Why Growth Investors Should Buy Electromed (ELMD) Now
Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates